Treatment of inherited platelet disorders

Haemophilia

Volumn 18, Issue SUPPL.4, 2012, Pages 161-165

  Seligsohn, U ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Bernard Soulier syndrome; Glanzmann thrombasthenia; Inherited platelet disorders; Platelet transfusion; Recombinant factor VIIa

Indexed keywords

ALLOANTIBODY; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; CONJUGATED ESTROGEN; DESMOPRESSIN; ESTROGEN; FIBRIN GLUE; GESTAGEN; GONADORELIN DERIVATIVE; HLA ANTIBODY; IRON; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

ALLOIMMUNIZATION; ARTERY THROMBOSIS; ARTICLE; BERNARD SOULIER DISEASE; BLEEDING; BLEEDING TIME; BLOOD COMPONENT THERAPY; BLOOD DONOR; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CONTINUOUS INFUSION; DRUG MEGADOSE; EPISTAXIS; FAMILY COUNSELING; FLUID RETENTION; FLUSHING; GASTROINTESTINAL HEMORRHAGE; GENETIC DISORDER; GINGIVA BLEEDING; GLANZMANN DISEASE; HEADACHE; HEART INFARCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHILIA A; HEMOSTASIS; HEPATITIS B; HLA MATCHING; HUMAN; HYPONATREMIA; HYPOTENSION; INFECTION RISK; IRON DEFICIENCY; MENARCHE; MENORRHAGIA; MOUTH HYGIENE; PATIENT MONITORING; POSTOPERATIVE HEMORRHAGE; POSTPARTUM HEMORRHAGE; PREGNANCY; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEIZURE; SIDE EFFECT; STROKE; SURGICAL PATIENT; TACHYCARDIA; THROMBOCYTE DISORDER; THROMBOCYTE TRANSFUSION; TOOTH EXTRACTION; TREATMENT OUTCOME; VACCINATION; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION DISORDERS, INHERITED; BLOOD PLATELET DISORDERS; COAGULANTS; FACTOR VIIA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HORMONES; HUMANS; MALE; PLATELET TRANSFUSION; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RECOMBINANT PROTEINS;

EID: 84862881766     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02842.x     Document Type: Article

References (31)

1. Bolton-Maggs PH, Chalmers EA, Collins PW et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006; 135: 603-33.
2. Alamelu J, Liesner R. Modern management of severe platelet function disorders. Br J Haematol 2010; 149: 813-23.
3. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977; 1: 869-72.
4. Kobrinsky NL, Israels ED, Gerrard JM et al. Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders. Lancet 1984; 1: 1145-8.
5. Schulman S, Johnsson H, Egberg N, Blomback M. DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. Thromb Res 1987; 45: 165-74.
6. Nieuwenhuis HK, Sixma JJ. 1-Desamino-8-D-arginine vasopressin (desmopressin) shortens the bleeding time in storage pool deficiency. Ann Intern Med 1988; 108: 65-7.
7. DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 1990; 33: 39-45.
8. Cattaneo M, Pareti FI, Zighetti ML, Lecchi A, Lombardi R, Mannucci PM. Platelet aggregation at high shear is impaired in patients with congenital defects of platelet secretion and is corrected by DDAVP: correlation with the bleeding time. J Lab Clin Med 1995; 125: 540-7.
9. Rao AK, Ghosh S, Sun L et al. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial. Thromb Haemost 1995; 74: 1071-8.
10. Fuse I, Higuchi W, Mito M, Aizawa Y. DDAVP normalized the bleeding time in patients with congenital platelet TxA2 receptor abnormality. Transfusion 2003; 43: 563-7.
11. Mannucci PM, Cattaneo M. Desmopression (DDAVP). In: Michelson AM ed. Platelets, Second edn. Amsterdam, The Netherlands: Elsevier, 2007: 1237-49.
12. Coppola A, Di Minno G. Desmopressin in inherited disorders of platelet function. Haemophilia 2008; 14: 31-9.
13. Cordova A, Barrios NJ, Ortiz I, Rivera E, Cadilla C, Santiago-Borrero PJ. Poor response to desmopressin acetate (DDAVP) in children with Hermansky-Pudlak syndrome. Pediatr Blood Cancer 2005; 44: 51-4.
14. Cattaneo M. Desmopressin in the treatment of patients with defects of platelet function. Haematologica 2002; 87: 1122-4.
15. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75: 981-2.
16. Poon MC, D'Oiron R, Von Depka M et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004; 2: 1096-103.
17. Poon MC. The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders. Transfus Med Rev 2007; 21: 223-36.
18. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
19. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003; 101: 1864-70.
20. Lisman T, Adelmeijer J, Heijnen HF, de Groot PG. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood 2004; 103: 1720-7.
21. Di Minno G, Coppola A, Di Minno MN, Poon MC. Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues. Thromb Haemost 2009; 102: 1157-64.
22. Almeida AM, Khair K, Hann I, Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003; 121: 477-81.
23. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
24. Santoro C, Rago A, Biondo F et al. Prevalence of allo-immunization anti-HLA and anti-integrin alphaIIbbeta3 in Glanzmann Thromboasthenia patients. Haemophilia 2010; 16: 805-12.
25. Lozano M, Cid J. The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility. Transfus Med Rev 2003; 17: 57-68.
26. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990; 75: 1383-95.
27. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822-34.
28. Markovitch O, Ellis M, Holzinger M, Goldberger S, Beyth Y. Severe juvenile vaginal bleeding due to Glanzmann's thrombasthenia: case report and review of the literature. Am J Hematol 1998; 57: 225-7.
29. Demers C, Derzko C, David M, Douglas J. Gynaecological and obstetric management of women with inherited bleeding disorders. Int J Gynaecol Obstet 2006; 95: 75-87.
30. Peitsidis P, Datta T, Pafilis I, Otomewo O, Tuddenham EG, Kadir RA. Bernard Soulier syndrome in pregnancy: a systematic review. Haemophilia 2010; 16: 584-91.
31. Siddiq S, Clark A, Mumford A. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia 2011; 17: e858-69.